Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Rogaratinib by Bayer for Solid Tumor: Likelihood of Approval
Rogaratinib is under clinical development by Bayer and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...